PDCD1 and non-small cell lung carcinoma: For instance, it was shown that NSCLC patients with baseline plasma citrulline levels higher than 20 μM (reflecting properly functioning enterocytes) more frequently received clinical benefits from the anti-PD-1 therapy and had longer PFS and OS than those with lower citrulline levels [8].